Anti-anxiety drugs use and cardiovascular outcomes in patients with myocardial infarction: A national wide assessment

Atherosclerosis

Volumn 235, Issue 2, 2014, Pages 496-502

  Wu, Cho Kai ^a,b   Huang, Yin Tseng ^c   Lee, Jen Kuang ^a,c,d   Jimmy Juang, Jyh Ming ^a   Tsai, Chia Ti ^a   Lai, Ling Pin ^a   Hwang, Juey Jen ^a   Chiang, Fu Tien ^a   Lin, Jiunn Lee ^a   Chen, Pau Chung ^e   Lin, Lian Yu ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^d Graduate Institute of Biomedical Electronics and Bioinformatics   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Anti anxiety; Cardiovascular; Myocardial infarction; Outcome

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPRAZOLAM; ANTIHYPERTENSIVE AGENT; ANXIOLYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BROMAZEPAM; BROTIZOLAM; BUSPIRONE; CALCIUM CHANNEL BLOCKING AGENT; CHLORDIAZEPOXIDE; CLOBAZAM; CLOPIDOGREL; DIAZEPAM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ESTAZOLAM; FLUNITRAZEPAM; FLURAZEPAM; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LORMETAZEPAM; MEDAZEPAM; MIDAZOLAM; NIMETAZEPAM; NITRAZEPAM; ORAL ANTIDIABETIC AGENT; OXAZEPAM; TRIAZOLAM; WARFARIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR MORTALITY; COMORBIDITY; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DOSE RESPONSE; FEMALE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SUDDEN DEATH; TAIWAN; EPIDEMIOLOGY; HEART FAILURE; MIDDLE AGED; MYOCARDIAL INFARCTION; STATISTICS AND NUMERICAL DATA;

ADULT; AGED; ANTI-ANXIETY AGENTS; DIAZEPAM; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK FACTORS; TAIWAN;

EID: 84921686107     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.05.918     Document Type: Article

References (27)

1. Sala V., Crepaldi T. Novel therapy for myocardial infarction: can HGF/Met be beneficial?. Cell Mol Life Sci 2011, 68:1703-1717.
2. Wrigt R.S., Anderson J.L., Adams C.D., Bridges C.R., Casey D.E., Ettinger S.M., et al. 2011 ACCF/AHA focused update of the guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011, 123:2022-2060.
3. Suls J., Bunde J. Anger, anxiety, and depression as risk factors for cardiovascular disease: the problems and implications of overlapping affective dispositions. Psychol Bull 2005, 131:260-300.
4. Shen B.J., Avivi Y.E., Todaro J.F., Spiro A., Laurenceau J.P., Ward K.D., et al. Anxiety characteristics independently and prospectively predict myocardial infarction in men the unique contribution of anxiety among psychologic factors. JAm Coll Cardiol 2008, 51:113-119.
5. Gorgels W.J., Oude Voshaar R.C., Mol A.J., van de Lisdonk E.H., van Balkom A.J., van den Hoogen H.J., et al. Discontinuation of long-term benzodiazepine use by sending a letter to users in family practice: a prospective controlled intervention study. Drug Alcohol Depend 2005, 78:49-56.
6. Isacson D., Carsjo K., Bergman U., Blackburn J.L. Long-term use of benzodiazepinesin a Swedish community: an eight-year follow-up. JClin Epidemiol 1992, 45:429-436.
7. Lagnaoui R., Depont F., Fourrier A., Abouelfath A., Bégaud B., Verdoux H., et al. Patterns and correlates of benzodiazepine use in the French general population. Eur J Clin Pharmacol 2004, 60:523-529.
8. Zandstra S.M., Van Rijswijk E., Rijnders C.A., Van De Lisdonk E.H., Bor J.H., Van Weel C., et al. Long-term benzodiazepine users in family practice: differences from short-term users in mental health, coping behaviour and psychological characteristics. Fam Pract 2004, 21:266-269.
9. Fang S.Y., Chen C.Y., Chang I.S., Wu C.H., Chang C.M., Lin K.M. Predictors of the incidence and discontinuation of long-term use of benzodiazepines: a population-based study. Drug Alcohol Depend 2009, 104:140-146.
10. Lu J.F., Hsiao W.C. Does universal health insurance make health care unaffordable? Lessons from Taiwan. Health Aff (Millwood) 2003, 22:77-88.
11. Chiang T.L. Taiwan's 1995 health care reform. Health Policy 1997, 39:225-239.
12. Tseng C.H. Mortality and causes of death in a national sample of diabetic patients in Taiwan. Diabetes Care 2004, 27:1605-1609.
13. Lin L.Y., Lee C.H., Yu C.C., Tsai C.T., Lai L.P., Hwang J.J., et al. Risk factors and incidence of ischemic stroke in Taiwanese with nonvalvular atrial fibrillation - a nation wide database analysis. Atherosclerosis 2011, 217:292-295.
14. Tu J.V., Austin P.C., Walld R., Roos L., Agras J., McDonald K.M. Development and validation of the Ontario acute myocardial infarction mortality prediction rules. JAm Coll Cardiol 2001, 37:992-997.
15. Kawachi I., Sparrow D., Vokonas P.S., Weiss S.T. Symptoms of anxiety and risk of coronary heart disease. The Normative Aging Study. Circulation 1994, 90:2225-2229.
16. Rosengren A., Hawken S., Ounpuu S., Sliwa K., Zubaid M., Almahmeed W.A., et al. Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13648 controls from 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364:953-962.
17. Thayer J.F., Friedman B.H., Borkovec T.D. Autonomic characteristics of generalized anxiety disorder and worry. Biol Psychiatry 1996, 39:255-266.
18. Grippo A.J., Johnson A.K. Biological mechanisms in the relationship between depression and heart disease. Neurosci Biobehav Rev 2002, 26:941-962.
19. Denollet J. DS14: standard assessment of negative affectivity, social inhibition, and Type D personality. Psychosom Med 2005, 67:89-97.
20. Stewart J.C., Janicki D.L., Muldoon M.F., Sutton-Tyrrell K., Kamarck T.W. Negative emotions and 3-year progression of subclinical atherosclerosis. Arch Gen Psychiatry 2007, 64:225-233.
21. Devlin J.W., Roberts R.J. Pharmacology of commonly used analgesics and sedatives in the ICU: benzodiazepines, propofol, and opioids. Anesthesiol Clin 2011, 29:567-585.
22. Sampol G., Rodes G., Rios J., Romero O., Lloberes P., Morell F. Acute hypercapnic respiratory failure in patients with sleep apneas. Arch Bronconeumol 2010, 46:466-472.
23. Kleiger R.E., Miller J.P., Bigger J.T., Moss A.J. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 1987, 59:256-262.
24. Colombo J., Shoemaker W.C., Belzberg H., Hatzakis G., Fathizadeh P., Demetriades D. Noninvasive monitoring of the autonomic nervous system and hemodynamics of patients with blunt and penetrating trauma. JTrauma 2008, 65:1364-1373.
25. van der Hooft C.S., Schoofs M.W., Ziere G., Hofman A., Pols H.A., Sturkenboom M.C., et al. Inappropriate benzodiazepine use in older adults and the risk of fracture. Br J Clin Pharmacol 2008, 66:276-282.
26. Wagner A.K., Zhang F., Soumerai S.B., Walker A.M., Gurwitz J.H., Glynn R.J., et al. Benzodiazepine use and hip fractures in the elderly: who is at greatest risk?. Arch Intern Med 2004, 164:1567-1572.
27. Wang P.S., Bohn R.L., Glynn R.J., Mogun H., Avorn J. Hazardous benzodiazepine regimens in the elderly: effects of half-life, dosage, and duration on risk of hip fracture. Am J Psychiatry 2001, 158:892-898.